Literature DB >> 20802530

MicroRNA dysregulation in gastric cancer: a new player enters the game.

W K K Wu1, C W Lee, C H Cho, D Fan, K Wu, J Yu, J J Y Sung.   

Abstract

Gastric carcinogenesis is a multistep process involving genetic and epigenetic alteration of protein-coding proto-oncogenes and tumor-suppressor genes. Recent discoveries have shed new light on the involvement of a class of noncoding RNA known as microRNA (miRNA) in gastric cancer. A substantial number of miRNAs show differential expression in gastric cancer tissues. Genes coding for these miRNAs have been characterized as novel proto-oncogenes and tumor-suppressor genes based on findings that these miRNAs control malignant phenotypes of gastric cancer cells. In this connection, miRNA dysregulation promotes cell-cycle progression, confers resistance to apoptosis, and enhances invasiveness and metastasis. Moreover, certain polymorphisms in miRNA genes are associated with increased risks for atrophic gastritis and gastric cancer, whereas circulating levels of miRNAs may serve as biomarkers for early diagnosis. Several miRNAs have also been shown to correlate with gastric cancer progression, and thus may be used as prognostic markers. Elucidating the biological aspects of miRNA dysregulation may help us better understand the pathogenesis of gastric cancer and promote the development of miRNA-directed therapeutics against this deadly disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20802530     DOI: 10.1038/onc.2010.352

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  138 in total

1.  Epidermal growth factor receptor-coamplified and overexpressed protein (VOPP1) is a putative oncogene in gastric cancer.

Authors:  Caiping Gao; Minghui Pang; Zhou Zhou; Size Long; Dandan Dong; Jiyun Yang; Mei Cao; Chumin Zhang; Shengxi Han; Liangping Li
Journal:  Clin Exp Med       Date:  2014-11-15       Impact factor: 3.984

2.  Methylation status of TRAF2 is associated with the diagnosis and prognosis of gastric cancer.

Authors:  Juan Zhang; Wei-Jie Dai; Xiao-Zhong Yang
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

3.  MicroRNA-223 functions as an oncogene in human gastric cancer by targeting FBXW7/hCdc4.

Authors:  Jinhai Li; Yuanyuan Guo; Xiaodi Liang; Ming Sun; Guoliang Wang; Wei De; Wenxi Wu
Journal:  J Cancer Res Clin Oncol       Date:  2012-01-22       Impact factor: 4.553

4.  MiR-197 induces Taxol resistance in human ovarian cancer cells by regulating NLK.

Authors:  Dongling Zou; Dong Wang; Rong Li; Ying Tang; Li Yuan; Xingtao Long; Qi Zhou
Journal:  Tumour Biol       Date:  2015-04-02

5.  MicroRNA 520d-3p inhibits gastric cancer cell proliferation, migration, and invasion by downregulating EphA2 expression.

Authors:  Ruixin Li; Weijie Yuan; Wenjuan Mei; Keda Yang; Zihua Chen
Journal:  Mol Cell Biochem       Date:  2014-07-26       Impact factor: 3.396

6.  MicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid Malignancies.

Authors:  Ronit Vogt Sionov
Journal:  ISRN Hematol       Date:  2013-01-29

7.  A functional variant at miR-132-3p, miR-212-3p, and miR-361-5p binding site in CD80 gene alters susceptibility to gastric cancer in a Chinese Han population.

Authors:  Ruirong Wu; Fuchao Li; Jianjie Zhu; Rong Tang; Qinghua Qi; Xinru Zhou; Rui Li; Weipeng Wang; Dong Hua; Weichang Chen
Journal:  Med Oncol       Date:  2014-07-01       Impact factor: 3.064

8.  Downregulation of miR-301a-3p sensitizes pancreatic cancer cells to gemcitabine treatment via PTEN.

Authors:  Xiang Xia; Kundong Zhang; Guangtao Luo; Gang Cen; Jun Cao; Kejian Huang; Zhengjun Qiu
Journal:  Am J Transl Res       Date:  2017-04-15       Impact factor: 4.060

9.  Downregulation of microRNA-142-3p and its tumor suppressor role in gastric cancer.

Authors:  Yi Wang; Zhidong Cao; Lanlan Wang; Siqi Liu; Jianqiang Cai
Journal:  Oncol Lett       Date:  2018-03-23       Impact factor: 2.967

10.  Down-regulation of microRNA-135b inhibited growth of cervical cancer cells by targeting FOXO1.

Authors:  Yue Xu; Shuhua Zhao; Manhua Cui; Qiang Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.